Exane Derivatives’s Chesapeake Energy Corporation CHK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Hold
0
754
2020
Q1
Hold
0
746
2019
Q4
Hold
0
681
2019
Q3
Hold
0
653
2018
Q4
Hold
0
-$4 757
2018
Q3
Hold
0
689
2018
Q2
Hold
0
682
2018
Q1
Sell
-13
Closed -$8.71K 624
2017
Q4
$10.6K Sell
13
-22
-63% -$17.1K ﹤0.01% 401
2017
Q3
$30.1K Sell
35
-3
-8% -$2.58K 0.01% 337
2017
Q2
$38.2K Sell
38
-9
-19% -$9.66K 0.01% 333
2017
Q1
$55.3K Buy
47
+6
+15% +$7.29K 0.01% 259
2016
Q4
$58.2K Buy
41
+1
+3% +$1.31K 0.01% 287
2016
Q3
$49.9K Buy
40
+3
+8% +$3.46K 0.01% 305
2016
Q2
$31.3K Sell
37
-86
-70% -$82.5K 0.01% 307
2016
Q1
$101K Buy
+123
New +$87.1K 0.01% 242
2015
Q4
Sell
-119
Closed -$148K 576
2015
Q3
$174K Sell
119
-185
-61% -$314K 0.02% 194
2015
Q2
$679K Sell
304
-153
-33% -$432K 0.07% 119
2015
Q1
$1.3M Buy
457
+99
+28% +$349K 0.14% 83
2014
Q4
$1.4M Buy
+358
New +$1.49M 0.19% 84

Other funds holding CHK

Exane Derivatives's CHK Position: Q2 2020 in Review

Exane Derivatives held its Chesapeake Energy Corporation (CHK) position steady in Q2 2020 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #754.

Exane Derivatives first reported a position in CHK in Q4 2014 and has held it in 12 quarters since. The position peaked at $1.4M in Q4 2014. 13 funds tracked by Wall St. Rank hold CHK as of Q2 2020.

  • Exane Derivatives held 0 shares of Chesapeake Energy Corporation worth $0 as of Q2 2020.
  • Exane Derivatives left its Chesapeake Energy Corporation share count unchanged in Q2 2020.
  • Chesapeake Energy Corporation made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2020, its #754 holding.
  • Exane Derivatives first reported a position in Chesapeake Energy Corporation in Q4 2014 and has held it in 12 quarters since.
  • Exane Derivatives's Chesapeake Energy Corporation position peaked at $1.4M in Q4 2014.
  • 13 funds tracked by Wall St. Rank held Chesapeake Energy Corporation as of Q2 2020.

Based on Exane Derivatives's 13F filing for Q2 2020, filed 10 Jul 2020.